Skip to main content

Table 4 Recurrence risk by Cox regression analysis of non-pCR carcinoma according to Neo-Bioscore and Clustered Neo-Bioscore of low and low-intermediate risks

From: Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response

Characteristics Neo-Bioscore Low risk
Clustered Neo-Bioscore
Low-intermediate
Clustered Neo-Bioscore
HRa (CI95%) HR (CI95%) HR (CI95%)
Menopausal status
 Premenopausal Reference Reference Reference
 Postmenopausal 0.75 (0.45–1.27) 0.73 (0.19–2.77) 0.91 (0.41–2.03)
Histological grade
 I/II Reference Reference Reference
 III 1.33 (0.77–2.30) 2.05 (0.32–13.27) 0.77 (0.34–1.74)
Ki-67
 0–20% Reference Reference Reference
 20–50% 2.29 (0.68–7.73) 0.76 (0.12–4.79) 2.39 (0.29–19.89)
  ≥ 50% 3.39 (0.99–11.58) 4.81 (0.41–56.41) 3.37 (0.41–27.57)
Estrogen receptor
 Allred 7–8 (≥70%) Reference Reference Reference
 Allred 2–6 (< 70%) 1.54 (0.49–4.88) 2.17 (0.23–20.02) 0.53 (0.15–1.82)
 Negative 1.35 (0.44–4.15) 1.33 (0.11–16.67) 1.39 (0.16–12.50)
HER2
 Negative Reference Reference Reference
 Positive 0.58 (0.15–2.28) 1.45 (0.34–6.17) 0.83 (0.20–3.50)
Tumor subtype
 A Reference Reference Reference
 B 0.50 (0.12–2.12) 0.53 (0.09–3.20) 1.10 (0.49–2.50)
 HER2 0.58 (0.15–2.28) 1.45 (0.34–6.17) 0.83 (0.20–3.50)
 TN 1.90 (0.49–7.30) 8.92 (0.94–84.93) 3.60 (1.19–10.92)
Clinical stage
 I/II Reference Reference Reference
 III 1.81 (0.88–3.75) 2.70 (0.60–12.21) 1.00 (0.38–2.66)
Pathological stage
 I Reference Reference Reference
 II 8.12 (2.40–27.53) 4.17 (0.47–37.33) 5.35 (1.19–24.01)
 III 16.24 (4.71–55.95) 13.00 (1.60–106.10) 6.56 (1.29–33.32)
  1. aHR Hazard ratio at 3 years